Table 2.
Clinical and demographic characteristics of the patient subset with class V LN on biopsy 2
| Biopsy 1 |
||||
|---|---|---|---|---|
| Variable | Total | Non-proliferative | Proliferative | P-value |
| (n = 56) | (n = 27) | (n = 29) | ||
| Age at biopsy 2, mean (s.d.), years | 37.7 (10.7) | 32.7 (9.5) | 0.04 | |
| Sex, n (%) | 0.462 | |||
| Female | 48 (85.7) | 22 (81.5) | 26 (89.7) | |
| Male | 8 (14.3) | 5 (18.5) | 3 (10.3) | |
| Race, n (%) | 0.25 | |||
| Asian | 5 (8.9) | 3 (11.1) | 2 (6.9) | |
| Black | 41 (73.2) | 21 (77.8) | 20 (69) | |
| White | 6 (10.7) | 3 (11.1) | 3 (10.3) | |
| Other | 4 (7.1) | 0 (0) | 4 (14.8) | |
| New eGFR < 15 after biopsy 2, n (%) | 0.052 | |||
| No | 51 (91) | 27 (100) | 24 (82.8) | |
| Yes | 5 (9) | 0 (0) | 5 (17.2) | |
| Follow up from biopsy 1, mean (s.d.), years | 12.5 (6.3) | 12.1 (7.0) | 13.0 (6.0) | 0.597 |
| Follow up from biopsy 2, mean (s.d.), years | 8.0 (5.1) | 7.9 (5.3) | 8.5 (5.1) | 0.679 |
| Time between biopsy 1 and 2, mean (s.d.), years | 4.5 (4.4) | 4.6 (4.3) | 4.5 (4.6) | 0.927 |
| eGFR 2–12 months before biopsy 2. mean (s.d.), mL/min/1.73m2 | 91.7 (32.4) | 95.2 (27.4) | 87.5 (36.7) | 0.396 |
| Urine pr/cr before biopsy 2, mean (s.d.) | 1.1 (1.3) | 1.0 (1.0) | 1.3 (1.5) | 0.361 |
| Nephrotic range, n (%) | 0.908 | |||
| No | 36 (64.3) | 18 (66.7) | 18 (62.1) | |
| Yes | 16 (28.6) | 7 (25.9) | 9 (31) | |
| Class at biopsy 1, n (%) | <0.001 | |||
| I | 1 (1.8) | 1 (3.7) | 0 (0) | |
| II | 4 (7.1) | 4 (14.8) | 0 (0) | |
| III | 3 (5.4) | 0 (0) | 3 (10.3) | |
| IV | 10 (17.9) | 0 (0) | 10 (34.5) | |
| Mixed | 16 (28.6) | 0 (0) | 16 (55.2) | |
| V | 22 (39.3) | 22 (81.5) | 0 (0) | |
| Anti-dsDNA, n (%) | 0.322 | |||
| No | 28 (50) | 15 (55.6) | 13 (44.8) | |
| Yes | 24 (42.9) | 9 (33.3) | 15 (51.7) | |
| C3, mean (s.d.), mg/dl | 95.1 (26.7) | 99.8 (31.1) | 90.8 (21.5) | 0.223 |
| C4, mean (s.d.), mg/dl | 19.9 (8.8) | 20.2 (9.6) | 19.7 (8.2) | 0.82 |
| HCQa, n (%) | 0.605 | |||
| No | 30 (53.6) | 13 (48.1) | 17 (58.6) | |
| Yes | 26 (46.4) | 14 (51.9) | 12 (41.4) | |
| Mycophenolatea, n (%) | 0.263 | |||
| No | 24 (42.9) | 9 (33.3) | 15 (51.7) | |
| Yes | 32 (57.1) | 18 (66.7) | 14 (48.3) | |
| CYCa, n (%) | 1 | |||
| No | 56 (100) | 27 (100) | 29 (100) | |
| Yes | 0 (0) | 0 (0) | 0 (0) | |
| AZAa, n (%) | 0.503 | |||
| No | 46 (82.1) | 24 (88.9) | 22 (75.9) | |
| Yes | 9 (16.1) | 3 (11.1) | 6 (20.7) | |
| Prednisonea, n (%) | 0.117 | |||
| No | 17 (30.4) | 5 (18.5) | 12 (41.4) | |
| Yes | 39 (69.6) | 22 (81.5) | 17 (58.6) | |
| ACE inhibitors or ARBsa, n (%) | 0.81 | |||
| No | 25 (44.6) | 13 (48.1) | 12 (41.4) | |
| Yes | 31 (55.4) | 14 (51.9) | 17 (58.6) | |
a
Only if confirmed treatment adherence. P-values were calculated using Fisher’s exact or Kruskal–Wallis test as appropriate.